Q3-osavuosiraportti
UUTTA
1 päivä sitten‧23 min
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
36 126
Myynti
Määrä
2 556
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 18 896 | - | - | ||
| 9 000 | - | - | ||
| 2 500 | - | - | ||
| 1 105 | - | - |
Ylin
1,078VWAP
Alin
1,04VaihtoMäärä
0,2 215 437
VWAP
Ylin
1,078Alin
1,04VaihtoMäärä
0,2 215 437
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 19.11. | |
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. |
Datan lähde: Millistream, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 päivä sittenContinued progress....... and revenue falls by 200.000 kr. compared to Q2 2025. The 2025 guidance has been cut for the 2nd time during 2025. The long-term vision, now 2028 instead of 2029, has also been significantly trimmed and the revenue target has been decimated by approx. 500 mio. kr. to now "only" 150-200 mio. kr. from 100 mio. usd in 2029.
·1 päivä sittenThe fact is, unfortunately, that they have been operating for over 20 years and still haven't shown to have anything they can sell and make money on.. Unfortunately, I have tied up too much money in that company, and am now starting to reduce with a loss, but conversely, they don't gain anything by staying invested either.
·1 päivä sitten · MuokattuWhat really drove the point home for me is that their expenditure is twice as high as their earnings. If they hadn't been on the stock market, the company would have gone bankrupt many years ago 🤔
·1 päivä sittenBioPorto's interim results for the third quarter of 2025 – Continued progress and continued NGAL sales growth https://via.ritzau.dk/pressemeddelelse/14683059/bioporto-as?lang=da·1 päivä sitten- ·3 päivää sittenWho is the new money? 1,07!!!!·3 päivää sittenThere has just been a webcast and here both NHN and CB said that they will buy shares in the next emission. It will be interesting to see how many shares they buy. Regarding who buys, it seems that they already have agreements in place with current and new investors, so I think they have the money secured, regardless of whether small investors buy shares or not.
- ·3 päivää sittenBioPorto (One-pager): Strategy reset "Fremadrettet" and capital raise support the 2027 roadmap https://www.inderes.dk/research/bioporto-one-pager-forward-strategy-reset-and-capital-raise-support-2027-roadmap?utm_source=nordnet&utm_medium=integration·3 päivää sittenHehehehe…there has been so much resetting in that company that most shareholders are sitting on large losses…without a chance for a reset. This is precisely the only thing this company has always been capable of delivering, clever talk and words, words, words.
·14.11.Bioporto has never been stronger in the clinic, where the first FDA approval was secured almost two years ago, or commercially, where NGAL sales are on a promising upward curve, which will truly turn upwards when the next FDA approval is expected in 2027. The adult market is expected to be about 20 times larger than the pediatric market. Last week's revised financing plan and minor downgrade caused smaller investors to sell off and sent the share price to a historical low. Large investors and institutional investors probably won't say thank you for this windfall, but have likely secured a good piece of the pie in this very promising life science company with today's private placement. It also bodes well that the support for the company comes from the large investors and BioPorto's board and management.·1 päivä sittenBut now there is progress(?) as one can always read in the financial report. Revenue has increased by a formidable 1% for the first nine months compared to last year. That's absolutely craaaazy. Some would indeed call it stagnation, and others decline when one also remembers there's something called inflation. And the EBITDA loss has increased to 63 mill from 51 compared to the first nine months. That's SOME KIND of progress. There's more spin in bioporto's announcements than there is in politicians'.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Q3-osavuosiraportti
UUTTA
1 päivä sitten‧23 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenContinued progress....... and revenue falls by 200.000 kr. compared to Q2 2025. The 2025 guidance has been cut for the 2nd time during 2025. The long-term vision, now 2028 instead of 2029, has also been significantly trimmed and the revenue target has been decimated by approx. 500 mio. kr. to now "only" 150-200 mio. kr. from 100 mio. usd in 2029.·1 päivä sittenThe fact is, unfortunately, that they have been operating for over 20 years and still haven't shown to have anything they can sell and make money on.. Unfortunately, I have tied up too much money in that company, and am now starting to reduce with a loss, but conversely, they don't gain anything by staying invested either.·1 päivä sitten · MuokattuWhat really drove the point home for me is that their expenditure is twice as high as their earnings. If they hadn't been on the stock market, the company would have gone bankrupt many years ago 🤔
- ·1 päivä sittenBioPorto's interim results for the third quarter of 2025 – Continued progress and continued NGAL sales growth https://via.ritzau.dk/pressemeddelelse/14683059/bioporto-as?lang=da·1 päivä sitten
- ·3 päivää sittenWho is the new money? 1,07!!!!·3 päivää sittenThere has just been a webcast and here both NHN and CB said that they will buy shares in the next emission. It will be interesting to see how many shares they buy. Regarding who buys, it seems that they already have agreements in place with current and new investors, so I think they have the money secured, regardless of whether small investors buy shares or not.
- ·3 päivää sittenBioPorto (One-pager): Strategy reset "Fremadrettet" and capital raise support the 2027 roadmap https://www.inderes.dk/research/bioporto-one-pager-forward-strategy-reset-and-capital-raise-support-2027-roadmap?utm_source=nordnet&utm_medium=integration·3 päivää sittenHehehehe…there has been so much resetting in that company that most shareholders are sitting on large losses…without a chance for a reset. This is precisely the only thing this company has always been capable of delivering, clever talk and words, words, words.
- ·14.11.Bioporto has never been stronger in the clinic, where the first FDA approval was secured almost two years ago, or commercially, where NGAL sales are on a promising upward curve, which will truly turn upwards when the next FDA approval is expected in 2027. The adult market is expected to be about 20 times larger than the pediatric market. Last week's revised financing plan and minor downgrade caused smaller investors to sell off and sent the share price to a historical low. Large investors and institutional investors probably won't say thank you for this windfall, but have likely secured a good piece of the pie in this very promising life science company with today's private placement. It also bodes well that the support for the company comes from the large investors and BioPorto's board and management.·1 päivä sittenBut now there is progress(?) as one can always read in the financial report. Revenue has increased by a formidable 1% for the first nine months compared to last year. That's absolutely craaaazy. Some would indeed call it stagnation, and others decline when one also remembers there's something called inflation. And the EBITDA loss has increased to 63 mill from 51 compared to the first nine months. That's SOME KIND of progress. There's more spin in bioporto's announcements than there is in politicians'.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
36 126
Myynti
Määrä
2 556
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 18 896 | - | - | ||
| 9 000 | - | - | ||
| 2 500 | - | - | ||
| 1 105 | - | - |
Ylin
1,078VWAP
Alin
1,04VaihtoMäärä
0,2 215 437
VWAP
Ylin
1,078Alin
1,04VaihtoMäärä
0,2 215 437
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 19.11. | |
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. |
Datan lähde: Millistream, Quartr
Q3-osavuosiraportti
UUTTA
1 päivä sitten‧23 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3-osavuosiraportti | 19.11. | |
| 2025 Q2-osavuosiraportti | 15.8. | |
| 2025 Q1-osavuosiraportti | 8.5. | |
| 2024 Yhtiökokous | 11.4. | |
| 2024 Q4-osavuosiraportti | 20.3. |
Datan lähde: Millistream, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 päivä sittenContinued progress....... and revenue falls by 200.000 kr. compared to Q2 2025. The 2025 guidance has been cut for the 2nd time during 2025. The long-term vision, now 2028 instead of 2029, has also been significantly trimmed and the revenue target has been decimated by approx. 500 mio. kr. to now "only" 150-200 mio. kr. from 100 mio. usd in 2029.·1 päivä sittenThe fact is, unfortunately, that they have been operating for over 20 years and still haven't shown to have anything they can sell and make money on.. Unfortunately, I have tied up too much money in that company, and am now starting to reduce with a loss, but conversely, they don't gain anything by staying invested either.·1 päivä sitten · MuokattuWhat really drove the point home for me is that their expenditure is twice as high as their earnings. If they hadn't been on the stock market, the company would have gone bankrupt many years ago 🤔
- ·1 päivä sittenBioPorto's interim results for the third quarter of 2025 – Continued progress and continued NGAL sales growth https://via.ritzau.dk/pressemeddelelse/14683059/bioporto-as?lang=da·1 päivä sitten
- ·3 päivää sittenWho is the new money? 1,07!!!!·3 päivää sittenThere has just been a webcast and here both NHN and CB said that they will buy shares in the next emission. It will be interesting to see how many shares they buy. Regarding who buys, it seems that they already have agreements in place with current and new investors, so I think they have the money secured, regardless of whether small investors buy shares or not.
- ·3 päivää sittenBioPorto (One-pager): Strategy reset "Fremadrettet" and capital raise support the 2027 roadmap https://www.inderes.dk/research/bioporto-one-pager-forward-strategy-reset-and-capital-raise-support-2027-roadmap?utm_source=nordnet&utm_medium=integration·3 päivää sittenHehehehe…there has been so much resetting in that company that most shareholders are sitting on large losses…without a chance for a reset. This is precisely the only thing this company has always been capable of delivering, clever talk and words, words, words.
- ·14.11.Bioporto has never been stronger in the clinic, where the first FDA approval was secured almost two years ago, or commercially, where NGAL sales are on a promising upward curve, which will truly turn upwards when the next FDA approval is expected in 2027. The adult market is expected to be about 20 times larger than the pediatric market. Last week's revised financing plan and minor downgrade caused smaller investors to sell off and sent the share price to a historical low. Large investors and institutional investors probably won't say thank you for this windfall, but have likely secured a good piece of the pie in this very promising life science company with today's private placement. It also bodes well that the support for the company comes from the large investors and BioPorto's board and management.·1 päivä sittenBut now there is progress(?) as one can always read in the financial report. Revenue has increased by a formidable 1% for the first nine months compared to last year. That's absolutely craaaazy. Some would indeed call it stagnation, and others decline when one also remembers there's something called inflation. And the EBITDA loss has increased to 63 mill from 51 compared to the first nine months. That's SOME KIND of progress. There's more spin in bioporto's announcements than there is in politicians'.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
36 126
Myynti
Määrä
2 556
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 18 896 | - | - | ||
| 9 000 | - | - | ||
| 2 500 | - | - | ||
| 1 105 | - | - |
Ylin
1,078VWAP
Alin
1,04VaihtoMäärä
0,2 215 437
VWAP
Ylin
1,078Alin
1,04VaihtoMäärä
0,2 215 437
Välittäjätilasto
Dataa ei löytynyt